New Hope for Kids With Rare Fatal Intestinal Disease

Children born with microvillus inclusion disease face a devastating reality: their intestines can't absorb nutrients, forcing them to rely on intravenous feeding just to survive. Now, a drug called crofelemer is offering these families something they've rarely had before—genuine hope.

Napo Pharmaceuticals recently held preliminary discussions with the FDA to evaluate breakthrough therapy designation for crofelemer as a treatment for this ultra-rare condition. The oral liquid medication has already shown promising results in two young patients, meaningfully reducing their need for weekly parenteral support, the intravenous nutrition that keeps them alive.

Microvillus inclusion disease affects only a handful of children worldwide. Without working intestines, these kids depend entirely on IV nutrition delivered through central lines, often requiring hospital stays and facing serious complications. Many don't survive past early childhood.

The early results represent a significant step forward. A pivotal randomized, placebo-controlled trial has already completed enrollment, and initial long-term results have been accepted for presentation at a major pediatric gastroenterology conference in June 2026.

The medication has received orphan drug designation in both the United States and European Union for MVID and short bowel syndrome, a status that recognizes the urgent need for treatments in rare diseases. These designations can help speed development and review processes.

Why This Inspires

This story matters because it shows how even the smallest patient populations aren't being forgotten. When a disease affects fewer than a hundred living children globally, pharmaceutical companies face enormous financial challenges in developing treatments. Yet teams of researchers, doctors, and advocates continue pushing forward.

The families living with MVID know every day counts. Parents watch their children endure daily IV infusions, frequent infections from central lines, and the constant threat of liver failure from long-term parenteral nutrition. Even preliminary proof that an oral medication might reduce these burdens represents a monumental shift.

While the FDA discussion was preliminary and doesn't guarantee approval, the fact that regulators are engaging seriously with this ultra-rare disease treatment signals recognition of the critical unmet need. The completed enrollment in the pivotal trial means answers are coming.

For the estimated hundred or so children worldwide living with MVID, crofelemer could mean fewer hours tethered to IV poles, less time in hospitals, and more time simply being kids.